Document is current
Any future updates will be listed below
-
Authors
Nakamura, Nobuhiko https://orcid.org/0000-0003-1682-7777
Morishita, Tetsuji https://orcid.org/0000-0002-7225-2819
Hayashi, Hiromi https://orcid.org/0000-0002-4599-5465
Okabe, Motohito https://orcid.org/0000-0002-5933-3868
Nakasone, Hideki https://orcid.org/0000-0001-5812-9315
Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Doki, Noriko https://orcid.org/0000-0002-8661-3179
Fukuda, Takahiro
Yoshihara, Satoshi https://orcid.org/0000-0002-8537-2422
Tanaka, Masatsugu
Nishida, Tetsuya
Hasegawa, Yuta
Matsuoka, Ken-ichi https://orcid.org/0000-0001-7955-8266
Sawa, Masashi
Eto, Tetsuya https://orcid.org/0000-0002-2630-493X
Onizuka, Makoto https://orcid.org/0000-0003-3864-0823
Katayama, Yuta https://orcid.org/0000-0001-5054-9104
Kato, Koji
Ishimaru, Fumihiko
Tabuchi, Ken
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Kanemura, Nobuhiro https://orcid.org/0000-0001-8449-9918
Teshima, Takanori https://orcid.org/0000-0002-0941-271X
- License Information
-
More Information
Article History
Received: 1 February 2025
Revised: 26 March 2025
Accepted: 31 March 2025
First Online: 17 April 2025
Competing interests
: NN received honoraria from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Sanofi, Novartis, MSD K.K., Sumitomo Pharma Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Meiji Seika Pharma Co., Ltd., and AstraZeneca K.K. HN received honoraria from Janssen Pharma and a scholarship from JCR Pharmaceuticals. NU received honoraria from Otsuka Pharmaceutical Co., Ltd., and AbbVie GK; research funding from Astellas Pharma Inc.; and scholarships from Chugai Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Kyowa Kirin Co., Ltd. TT received honoraria from Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Novartis Pharma K.K., and Bristol-Myers Squibb Co.; research funding from Astellas Pharma Inc., LUCA Science Inc., Otsuka Pharmaceutical Co., Ltd., Priothera SAS, PharmaEssentia Japan K.K., AbbVie GK, IQVIA Services Japan GK, Kyowa Kirin Co., Ltd., CMIC Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb Co., Janssen Pharma, and CSL Behring K.K.; scholarships from Asahi Kasei Pharma Corp., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; and support for an endowed chair from the International Advanced Medical Organization. The remaining authors have no conflicts of interest to disclose.
: This study was approved by the Data Management Committee of the JDCHCT and the Medical Review Board of Gifu University Graduate School of Medicine (#2023-305). Written informed consent was obtained from all participants before registration in TRUMP 2. All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki and its later amendments. No identifiable images or other personal details of participants are presented in this manuscript.
